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Background: Modified cell-based angiogenic therapy has become a promising novel strategy for ischemic heart
and limb diseases. Most studies focused on myoblast, endothelial cell progenitors or bone marrow mesenchymal
stromal cells transplantation. Yet adipose-derived stromal cells (in contrast to bone marrow) are abundantly
available and can be easily harvested during surgery or liposuction. Due to high paracrine activity and availability
ADSCs appear to be a preferable cell type for cardiovascular therapy. Still neither genetic modification of human
ADSC nor in vivo therapeutic potential of modified ADSC have been thoroughly studied. Presented work is sought
to evaluate angiogenic efficacy of modified ADSCs transplantation to ischemic tissue.
Materials and methods: Human ADSCs were transduced using recombinant adeno-associated virus (rAAV)
serotype 2 encoding human VEGF165. The influence of genetic modification on functional properties of ADSCs and
their angiogenic potential in animal models were studied.
Results: We obtained AAV-modified ADSC with substantially increased secretion of VEGF (VEGF-ADSCs). Transduced
ADSCs retained their adipogenic and osteogenic differentiation capacities and adhesion properties. The level of
angiopoetin-1 mRNA was significantly increased in VEGF-ADSC compared to unmodified cells yet expression of
FGF-2, HGF and urokinase did not change. Using matrigel implant model in mice it was shown that VEGF-ADSC
substantially stimulated implant vascularization with paralleling increase of capillaries and arterioles. In murine hind
limb ischemia test we found significant reperfusion and revascularization after intramuscular transplantation of
VEGF-ADSC compared to controls with no evidence of angioma formation.
Conclusions: Transplantation of AAV-VEGF- gene modified hADSC resulted in stronger therapeutic effects in the
ischemic skeletal muscle and may be a promising clinical treatment for therapeutic angiogenesis.
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Despite advances in revascularization techniques, the
treatment of ischemic heart and limb diseases remains a
worldwide problem. Therapeutic angiogenesis represents
alternative new strategy for ischemia resolution that
utilizes regenerative capacity of human body and
stimulates natural process of vessel growth, remodeling
and tissue revascularization [1].
Commonly adopted approaches for therapeutic
angiogenesis include direct introduction of recombinant
growth factors and gene therapy. Yet clinical trials have
shown several drawbacks of these modalities. Thus low
efficacy of recombinant protein administration is explained
by dissemination after injection and rapid degradation of
therapeutic agent, which requires multiple and long-term
infusions thus leading to tremendous expenses [2,3].
Delivery of cDNA coding angiogenic factors via different
expression mammalian vectors (plasmids, recombinant
viruses) was found more feasible and allowed to achieve
great improvement in some cases yet efficacy was still not
high enough especially in double blind placebo controlled
trials [4]. Many authors discussed possible reasons of
gene therapy low efficacy and most of them are univocal to
emphasize transfection efficacy and transient transgene
expression after plasmid delivery. This can be circumvented
by administration of viral vectors but their use is limited
due to possible danger of insertional mutagenesis and
immune reactions [5,6].
Recently, autologous transplantation of bone marrow
stromal cells or endothelial progenitor cells has been
shown to enhance angiogenesis and peripheral blood flow
[7-9]. However, the regenerative capacity of these cells
decreases with age and in patients with co-morbidities such
as diabetes mellitus which reduces efficacy of autologous
cell administration. Moreover, limited cell viability after
transplantation into ischemic tissues also restricts their
angiogenic potential [10-12].
It was shown in several experimental studies that
this problem could be circumvented by gene modified
cell therapy strategy utilizing stem or progenitor cells
overexpressing angiogenic proteins [13,14]. To develop a
feasible and potent gene modified cell therapy for ischemic
diseases the cells should be both effective and accessible in
large numbers as well as the chosen viral vector should be
both safe and effective in terms of gene delivery. The
majority of experimental studies have evaluated gene
modified bone marrow stromal cells or endothelial
progenitor cells for ischemia treatment [15-17]. However,
cells extracted from bone marrow or peripheral blood after
mobilization are available in limited numbers and as for
bone marrow cells painful aspiration procedure is required.
In contrast to bone marrow or myoblasts, stromal
fraction of adipose tissue contains an abundant population
of multipotent stem cells that can be easily harvested inhigh numbers by minimally invasive surgical techniques
[18-21]. These adipose –derived stromal cells (ADSCs)
share common properties with bone marrow stromal cells
and represent a very convenient object for therapeutic
use. However the best development of ADSC for
angiogenic therapy still needs to be determined.
As for genetic modification of cells the choice of safe and
effective gene transfer vector as well as the appropriate
transgene determines the quality and safety of the cell
product affecting the efficacy of modified cell based
therapy. Recombinant adeno-associated viruses (rAAV) are
one of the most promising and versatile tools in this field
due to low immunogenicity and high transduction potency
in vitro in many types of both - dividing and non-dividing
mammalian cells. Besides that until now no human disease
caused by AAV has been identified [22].
In this study we genetically modified human ADSCs
with a key regulator of angiogenesis – VEGF165 [23]
via rAAV-transduction and then evaluated effects of
rAAV-transduction and VEGF165 overexpression on
human ADSC growth, differentiation capacity, adhesion
and angiogenic factor expression as well as revascularization
and functional improvement after intramuscular injection
in a mice hind limb model.
Methods
Cell culture
Human embryonic kidney (НЕК-293Т) cell line was
purchased from ATCC and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine
serum (FBS) (both Gibco, USA) and 1% antibiotic/
antimycotic solution. НЕК-293Т were maintained at <50%
confluency at 37°C/5% CO2 and passaged using 0.01%
EDTA/trypsin solution (Gybco, USA).
Human ADSC were isolated from abdominal
subcutaneous adipose tissue harvested during surgical oper-
ations from patients at age within 32–60 (mean 49.2±9.8)
years. All donors gave informed consent for harvesting of
their adipose tissue. Donors with infectious or systemic
diseases or malignancies were not included in the study.
Adipose tissue was washed extensively with 2 volumes of
phosphate-buffered saline (PBS) and then digested at
37°C for 1 h with equal volumes of collagenase (final
concentration 66.7 U/ml, Sigma Aldrich, USA) and
dispase (final concentration 10 U/ml, BD, USA). Enzyme
activity was neutralized by an equal volume of DMEM/10%
FBS and suspension was centrifuged at 200 g for 10 min.
Cell pellet was resuspended in DMEM/10%FBS and filtered
through 40 μm nylon cell strainer (BD Biosciences, USA).
Cells were collected by centrifugation, resuspended in
AdvanceStem basal medium for human undifferentiated
mesenchymal stem cells (HyClone, USA) containing 10% of
Advance stem cell growth supplement (CGS) (HyClone,
USA), 1% antibiotic/antimycotic solution (culture medium).
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erythrocytes were removed by routine medium changes.
ADSC culture was maintained at sub-confluent levels
(<80% confluency) at 37°C/5% CO2 and passaged using
HyQtase (HyClone, USA).
DNA constructs production of rAAV particles and cell
transduction
The Hind3/EcoR1 fragment containing human VEGF165
gene was excised from pcDNA3-hVEGF constructed
previously [24]. Subsequently it was cloned together with
the “stuffer” EcoR1/Xho1 fragment of pCMV-LUC-KEB
(а kind gift from «MonA» LLC, Russia) into pAAV-MCS
vector (Stratagene, USA), digested by Hind3 and Xho1 to
generate pAAV-VEGF165. The stuffer DNA lacking
complete open reading frames and RNA degradation
signals was used to increase the size of transgene insert
for proper incapsidation of recombinant virus [25].
Restriction enzymes were purchased from Fermentas,
Lithuania. All necessary plasmid constructs were amplified
in DH5α bacterial cells and subsequently purified using
Endofree Plasmid Maxi Kit (Qiagen, Germany).
Generation of recombinant AAV particles was
performed in HEK293T cells using AAV Helper-Free
System (Stratagene, USA). Small-scale vector preparations
were made in 100 mm dishes by cotransfection of
HEK293T cells with plasmids pAAV-RC, pHelper
(Stratagene, USA) and vector plasmid pAAV-hrGFP
(Stratagene, USA) or pAAV-hVEGF to produce GFP or
hVEGF coding rAAV respectively. Cells that reached 80%
confluency were transfected using calcium-phosphate co-
precipitation method with 10 μg of each plasmid per dish.
Transfected cultures were maintained for 54 h at 37°C in
DMEM supplemented with 10% FBS. Thereafter cells
were detached and collected by centrifugation at 200 g for
10 min. Cell pellet was resuspended with 1 ml of PBS (per
culture dish) and was subject to four freeze–thaw cycles
(liquid nitrogen/37°C water bath) vortexing after each
thaw. Cell lysate was then incubated with 50 U/ml of
Benzonase (Merck, Germany) at 37°C for 30 min to digest
cellular nucleic acids. Cell debris was removed by centrifu-
gation at 5000 g for 25 minutes at room temperature and
the supernatant (viral stock) was aliquoted and stored
at −70°C until use.
One day prior to transduction human ADSC were
seeded into 100 mm plates at concentration of 6×105
cells/dish in culture medium. Thereafter medium was
removed, cells were washed twice with PBS and the
respective medium without CGS was added together with
1–2 ml of viral lysate per dish. 3 h after infection equal
volume of medium containing 20% CGS was added to
yield a final concentration of 10% CGS. Infected cells were
cultured for 48 h and then the percentage of viable cells
was determined by trypan blue exclusion.Western blotting and ELISA
Conditioned medium samples were assayed to determine
human VEGF165 secretion in ADSC culture. One day
prior to conditioning gene modified and untreated
ADSC were seeded in 60 mm dishes at density of
105cells/dish. Thereafter cells were washed twice with
PBS and then respective CGS-free media was added.
After 48 h of incubation at 37°C/5%CO2 medium was
collected and centrifuged at 300 g for 10 min. Collected
supernatant was stored at −70°C or used for enzyme-
linked immunosorbent assay (ELISA). VEGF165 concen-
tration in condition media samples was measured using
human VEGF Quantikine Kit (R&D Systems, USA) fol-
lowing manufacturer’s protocol. For western blotting
analysis conditioned media samples were concentrated
up to 60-fold using Amicon Ultra–4 units (10000 kDa,
Millipore, USA). Concentrated samples were used for
SDS-denaturing electrophoresis in a polyacrilamide gel
under non-reducing conditions according to standard
procedures. Recombinant human VEGF165 (BD Bio-
sciences, USA) was used as a positive control. Separated
proteins were transferred to a PVDF membrane
(Millipore, USA) with subsequent staining by mono-
clonal mouse antibodies against human VEGF165 (BD
Biosciences, USA) overnight at 4°C and with secondary
polyclonal HRP-conjugated goat anti-mouse IgG anti-
bodies (Jackson ImmunoResearch, USA) for 1 hour at
room temperature. Two-component chemiluminescent
substrate system ECL™ (Amersham Biosciences, USA)
was used for detection.
ADSC proliferation activity assay
To assess population doubling time (PDT) of gene
modified (transduced with rAAV at passage 1) or un-
treated ADSC (passage 2) seeded on 6-well plates (2 ×
104 cells/well). After a 9 day incubation average cell
numbers for three wells were obtained using a
hemocytometer chamber. PDT was calculated as follows:
PDT ¼ log2ð Þ  t= log Nt=N0ð Þð Þ
where t is period of incubation (hours), Nt – endpoint
amount of cells, N0 – initial number of cells.
ADSC cell cycle stage analysis by flow cytometry
ADSC were harvested by 0.25% trypsin/EDTA solution
and then fixed in ice-cold 70% ethanol for 2 h following
a 30 min incubation in propidium iodide solution
(50 μg/ml) containing 200 μg/ml RNAase А (Invitrogen,
USA) and 0.1% Triton X-100. ModFit LT 3.2 software
(Verity Software House, USA) was used for analysis of
cell distribution over cell cycle stages according to inten-
sity of propidium iodide fluorescence in a wavelength
range of 600–625 nm (excitation wavelength - 488 nm).
Shevchenko et al. Journal of Translational Medicine 2013, 11:138 Page 4 of 18
http://www.translational-medicine.com/content/11/1/138Results are presented as a percentage of cells in S + G2/
M stages.
Apoptosis assay
Analysis of spontaneous apoptosis frequency in ADSC
culture was performed using Annexin-V FITC Apop-
tosis Kit (Invitrogen, USA) according to manufacturer’s
protocol.
Adipogenic, osteogenic and endothelial differentiation of
ADSC
Gene modified and untransduced ADSC (passage 3)
were seeded in duplicate on 6-well plates and main-
tained in culture medium to reach approximately 90%
confluency. To promote adipogenic and osteogenic differ-
entiation of ADSC Mesenchуmal Stem Cell Adipogenesis
Kit and Mesenchymal Stem Cell Osteogenesis Kit
(Millipore, USA) were used according the manufacturer’s
protocol. For endothelial differentiation ADSC were
cultured in EGM-2 medium (Lonza, Switzerland) for
14 days. ADSC seeded at the same density and maintained
in standard culture medium were used as negative
control.
To confirm adipogenesis intracellular lipid droplets were
detected using Oil red O staining reagent (Millipore,
USA) 2 weeks after induction. To confirm osteogenesis
Alizarine Red C staining was used to detect extracellular
matrix mineralization 2 and 3 weeks post induction.
Endothelial cells were stained for CD31 and VEGFR2
surface antigens and cell counts were obtained using flow
cytometry.
Cell attachment assay
Human adhesion molecule solutions diluted with PBS to
a final concentration of 100 μg/ml for collagen type
1 (IMTEK, Russia), 10 μg/ml for vitronectin (Sigma
Aldrich, USA), 50 μg/ml for fibronectin (IMTEK, Russia)
and 100 μg/ml for laminin (Sigma Aldrich, USA) were
added to corresponding wells of a 96-well plate and in-
cubated at 4°C overnight. Blank wells were left uncoated
to determine 100% attachment at three cell concentra-
tions and background binding of crystal violet to plastic.
After incubation and aspiration of liquid excess wells
were washed by PBS and blocked by 0.2% bovine serum
albumin for 60 min at room temperature. Wells for
100% attachment were not blocked. The ADSC, GFP-
ADSC, VEGF-ADSC (all at passage 3) cell suspensions
with concentration of 5×105cells/ml were prepared in
prewarmed DMEM gassed with 5% CO2. To estimate
100% attachment, additional cell dilutions to 20, 50, and
100% of the working cell suspension were prepared in
the same medium. Cells were incubated at 37°C in a
15 ml polypropylene tube with lid off for 10 min in CO2
incubator. Thereafter 50 μl of cell suspension togetherwith an equal volume of PBS was added to each well.
After 40 min of incubation nonadherent cells in experi-
mental wells were removed by gently washing the well
three times with PBS. Attached cells were formalin-fixed
for 30 min at room temperature and washed three times
with distilled water. In “20%”, “50%” and “100%” wells
cells were fixed immediately after incubation. Fixed cells
were stained with 0.1% crystal violet for 30 min at room
temperature, washed again with distilled water and air-
dried. The dye was solubilized in 10% acetic acid by
incubating plate on orbital shaker for 5 min at room
temperature. Absorbance at 570 nm was measured using
a plate Multiscan Ascent reader (Thermo Fisher Scientific,
USA). Data from “20%”, “50%” and “100%” wells was used
to determine the value for 100% attachment, and then
experimental data was expressed as percentage.
Flow cytometry
To analyze expression of surface antigens human ADSC
were stained by specific antibodies: hVEGFR1/FLT1-PE
(R&D Systems, USA), hVEGFR2/KDR-APC (R&D Sys-
tems, USA), CD31-FITC (BD Biosciences, USA), CD140B
(PDGFRβ)–PE (BD Biosciences, USA). Antigen expres-
sion analysis was performed on cell sorter MoFlo
(DakoCytomation, Denmark) or flow cytometry scanner
BD FACS CantoTM II (BD Pharmingen, USA). 10 000
events were acquired and analyzed for antigen expression.
Quantitative polymerase chain reaction
Total RNA was isolated and purified using RNase
Miniprep Kit (Qiagen, USA) according to manufacturer’s
protocol. RNA was used for reverse transcription using
RevertAid™ first strand cDNA synthesis kit with oligo
(dT) primers (Fermentas, Lithuania). Quantitative poly-
merase chain reaction (qPCR) was performed using
primers specific for human VEGF165, ANGPT1, HGF,
FGF2 and PLAU mRNAs. The following primers were







GGGTCGCTCTTCTCCC; PLAU sense, 5’-TCAAAAAC
CTGCTATGAGGGGA, antisense, 5’-GGGCATGGTACG
TTTGCTG, β-actin gene: sense, 5’-CCTGGCACCCAG
CACAAT; antisense, 5’-GGGCCGGACTCGTCATAC,
GAPDH gene: sense, 5’-TGCACCACCAACTGCTTAGC,
antisense, 5’-GGCATGGACTGTGGTCATGAG. Quan-
titative polymerase chain reaction was performed on
iCycler iQ™5 real-time PCR detection system (Bio-Rad,
USA). SYBR Green PCR mix kit and custom primers were
purchased from Syntol, Russia. PCR conditions were: 50°C
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included denaturation at 95°C (15 sec), annealing at 61°C
(for VEGF, HGF, FGF2, PLAU) and 63°C (for ANGPT1)
for 30 sec both, 72°C (extension, 30 sec). A melt-curve
analysis immediately followed amplification and com-
prised of denaturation at 95°C (60 sec), cooling to 60°C
and a gradient rise of temperature to 95°C with 0.5°C step
and continuous acquisition of fluorescence decline. To
further confirm specificity of amplification PCR product
was analyzed by electrophoresis on 1% agarose gel in tris-
acetate-EDTA buffer.Animals
8–10 week-old male BALB/c NUDE mice were pur-
chased from Pushchino nursery (Pushchino, Russia). All
experimental procedures were performed according to
the “Rules for carrying out experiments using laboratory
animals” of Russian Cardiology Research and Production
Center.Matrigel plug assay
Human ADSC at passage 3 were collected by HyQTase
treatment and resuspended in PBS (5×106cells/ml). Vo-
lume of 400 μl liquid Matrigel™ matrix (BD Biosciences,
USA) was mixed with 100 μl of one of the following: PBS
as negative control, 5×105 untreated or gene modified
ADSC in PBS. Obtained mixtures were injected subcuta-
neously into inguinal region of BALB/с NUDE mice
(n=40) for subsequent analysis of blood vessel formation
and sprouting mediated by paracrine action of cells.
Animals were equally divided into 4 groups. Negative con-
trol group received matrigel with PBS (“PBS” group) while
three experimental groups received injections of matrigel
mixed with ADSC, GFP-ADSC or VEGF-ADSC (“ADSC”,
“GFP-ADSC”, “VEGF-ADSC” groups). At day 14 animals
were sacrificed and matrigel plugs were harvested for
subsequent immunostaining.Hind limb ischemia model
Ten week-old male BALB/с NUDE mice were ana-
esthetized by intraperitoneal injection of 0.3 ml of 2.5%
avertin. Femoral artery was separated in its distal part
and ligated proximal to its popliteal bifurcation (keeping
v. femoralis and n. ischiadicus intact). ADSC, GFP-
ADSC or VEGF-ADSC (5×105 cells per animal) were
resuspended in 150 μl of PBS, and injected in 3 equally
divided doses to m. tibialis anterior, m. gastrocnemius
and m. biceps femoris to generate three experimental
animal groups: “GFP-ADSC”, “VEGF-ADSC”, “ADSC”
(14 animals per group). PBS (150 μl) was injected in
negative control “PBS” group. Blood flow was subse-
quently measured by laser Doppler imaging.Laser doppler imaging
Subcutaneous blood flow was measured on plantar side
of hind limb using Laser Doppler Imaging System
(Moor, UK). Animals were narcotized by inhalation of 1-
2% isoflurane/oxygen mixture. Blood flow was measured
immediately after ischemia induction and then every
4 days until day 20. Data from three consecutive mea-
surements obtained within 5 minutes with less than 10%
deviation was taken for statistical analysis. To exclude
influence of external factors data was presented as mean
ratio of blood flow in ischemic to healthy limb of the
same animal.
Muscle explants
M. tibialis anterior explant culture was prepared on
matrigel according to Jang et al. [26] protocol and cul-
tured in M199 medium (Gibco, USA), containing 2% FBS.
At day 3 and 7 medium was collected for determination
of human VEGF165 concentration by ELISA.
Specimen preparation and histological analysis
At designated period (day 20 for muscles, day 14 for
matrigel plugs) animals were sacrificed by lethal isoflurane
dose followed by cervical dislocation. Afterwards m.
tibialis anterior or matrigel implants respectively were
harvested, embedded in O.C.T. Tissue-Tek media (Sakura,
Japan), frozen in liquid nitrogen and stored at −80°C.
Serial frozen sections (7 μm thick) were prepared for
histological analysis. For immunofluorescent staining sec-
tions were formalin-fixed and then immunolabeled with
rabbit anti-mouse FITC-SMA (Sigma-Aldrich, USA) and
rat anti-mouse CD31 (BD Biosciences, USA) primary anti-
bodies. Secondary antibodies donkey anti-rat IgG/Alexa
Fluor 594 (Invitrogen, USA) were used. Cell nuclei were
counterstained with DAPI. Stained sections were mounted
in aqueous-based medium for subsequent microscopy.
For muscle necrosis analysis we used routine hemato-
xylin-eosin staining of formalin-fixed muscle sections.
Necrotic tissue was defined by loss of fiber morphology,
cytoplasm disruption, inflammatory cells infiltration and
fibrosis.
Microphotographs were taken with Zeiss Axiovert
200 M fluorescent microscope under 100x magnification
in 5-7/plug and 7-11/muscle random fields of view
(FOV) on an area that covered ≥80% of the section.
Manual capillary (CD31+ structures) and arteriolar
(SMA + blood vessels with CD31+ inner layer) counts
per FOV were made by two independent persons and
used to obtain mean values for section, animal or group
followed by statistical analysis.
Statistical analysis
Results were analyzed in Statsoft Statistica 6.0 (Statsoft,
USA). Data is expressed as means±standard deviation.
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ficance. Statistical data distribution was analyzed using a
Shapiro-Wilk criterion and appropriate (Student or
Mann–Whitney) method was applied to determine
statistical significance.
Results
Effective transduction of human ADSC by adeno-
associated virus serotype 2
Low-passage human ADSC obtained from different
donors were transduced using rAAV encoding GFP to
assess gene delivery efficacy. Transduced to total cells
ratio was counted by flow cytometry. GFP-positive ADSC
(GFP-ADSC) were detected as early as day 2 after viral
infection. Maximum number of positive cells (65.6±3%)
and highest GFP-fluorescence intensity was reached by
day 4–5 (Figure 1). GFP signal was detectable for at least
30 days. At day 15 and 30 flow cytometry showed that
45±2% and 25±1.5% of ADSC were GFP-positive respec-
tively. Transduced culture showed about 10% of trypan
blue stained cells, indicating moderate effect of rAAV on
ADSC viability.
Increase of VEGF expression and secretion after rAAV
transduction of human ADSC
To obtain gene modified ADSC we constructed rAAV
vector encoding human VEGF165. In ADSC transduced
by rAAV-VEGF (VEGF-ADSC) VEGF165 mRNA level
increased 80±15-fold compared to basal expression in
unmodified ADSC or GFP-ADSC (Figure 2A). Protein
production was analyzed by Western blotting and
ELISA. Data presented at Figure 2B, C shows that in
VEGF-ADSC secretion of VEGF increased 45-50-fold
(4.5±1.8 ng/ml/105 cells) compared to unmodified cells
(0.1±0.02 ng/ml/105 cells) or GFP-ADSC (0.09±0.02 ng/
ml/105 cells). VEGF concentration in conditioned medium
decreased over time during VEGF-ADSC cultivation but
remained 30-fold higher (2.9±1.1 ng/ml/105 cells) than in
controls (0.09 ± 0.02 ng/ml/105 cells) at day 30 postFigure 1 Human ADSC transduction by recombinant adeno-associate
4 after transduction by rAAV. B. Representative image of GFP-positive hum
are counterstained by DAPI. Data obtained from a total of 10 donors.transduction. Material from a total of 10 donors was used
to obtain mean values of VEGF expression increase.
rAAV-mediated modification of human ADSC suppresses
their proliferation activity yet does not influence
apoptosis
We found that proliferation rate of VEGF-ADSC and
GFP-ADSC was reduced compared to unmodified cells
(Figure 3A). ADSC population doubling time was 61.3±7 h,
while for GFP-ADSC and VEGF-ADSC it was 116.9±11
and 145.4±12 h respectively (n=5, p<0.01 vs unmodified
cells). At the same time spontaneous apoptosis rate in all
three cell cultures was comparable and comprised about
2±0.5% of total cell population.
Analysis of cell cycle stages distribution in ADSC, GFP-
ADSC and VEGF-ADSC cultures (Figure 3B) showed that
number of cells in S-G2 stages was more than 1.5-fold
lower in modified cells: GFP-ADSC (16±4% cells) and
VEGF-ADSC (13±6% cells) compared to unmodified
ADSC (25±3% cells; n=3; p<0.05 vs unmodified cells).
ADSC adhesion does not change after genetic
modification
Interactions with extracellular matrix proteins play
important role in incorporation and integration to reci-
pient’s tissue, cell viability and their functional properties
upon transplantation. ADSC did adhere on main extra-
cellular protein collagen type 1 as well as vitronectin
and fibronectin while almost none of cells attached to
laminin-coated plastic. We did not observe statistically
significant differences in adhesion properties between
ADSC, GFP-ADSC and VEGF-ADSC cultures (Figure 4).
Modified ADSC retain their adipogenic, osteogenic and
endothelial differentiation potential in vitro
To analyze potential influence of viral transduction and
transgene overexpression on differentiation capacity of
gene modified cells we performed experiments on adipo-
genic and osteogenic differentiation of ADSC.d virus. A. GFP-positive cell count by FACS in GFP-ADSC culture at day
an ADSC (green) transduced by rAAV, 100 ×magnification. Cell nuclei
Figure 2 Validation of VEGF165 expression in AAV-modified
VEGF-ADSC. A. VEGFA expression level in human ADSC 10 days
after AAV transduction determined by quantitative PCR. B, C.
Analysis of VEGF secretion by GFP-ADSC, VEGF-ADSC and
unmodified cells using ELISA (B) and immunoblotting (C). In
immunosorbent assay protein content was determined in
conditioned media samples obtained at days 7 and 30 post genetic
modification of ADSC.
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ADSC stained with Oil Red O reagent after 14 days of
incubation in adipogenic media showed >30% of differ-
entiated (visualized by intracellular lipid droplets accu-
mulation) cells (Figure 5). Oil Red O+ cell count did not
reveal statistically significant differences in both GFP-
ADSC (33.7±8.1%) and VEGF-ADSC (34.1±11.5%) as
well as unmodified ADSC (34.3±11.7%). Similar results
were obtained in osteogenic differentiation assay of
ADSC. It was confirmed by Alizarin Red C staining that
detects extracellular matrix mineralization. At 14 days of
incubation in osteogenic media we detected dye-positive
cells in ADSC, GFP-ADSC, VEGF-ADSC culture. At day
21 it was followed by dramatic increase of extracellularmatrix calcification in both - modified and untreated
cells without significant differences (Figure 5).
Taking into account mitogenic activity of VEGF we
analyzed possible effect of genetic modification and VEGF
overexpression on endothelial cell fraction in VEGF-
ADSC. Using flow cytometry we determined amount of
cells that carry CD31 and VEGFR2 endothelial markers in
ADSC, GFP-ADSC and VEGF-ADSC (rAAV-modified at
passage 1) cultures at passage 2. Less than 1.5% of CD31,
VEGFR2-positive cells were detected in all three popu-
lations. Subsequently modified and untreated ADSC at
passage 2 that reached >90% confluency were subject to
incubation in EGM-2 medium to stimulate endothelial
differentiation. After 14 days of cultivation in EGM-2
repeated analysis of CD31 and VEGFR2 expression
showed that percentage of endothelial marker-positive
cells did not change and remained about 1% in all assayed
cultures.
Level of angiopoietin-1 mRNA increases in VEGF-ADSC
Using qPCR we studied potential impact of genetic mo-
dification and augmented VEGF secretion on expression
activity of hepatocyte growth factor (HGF), fibroblast
growth factor-2 (FGF2), angiopoietin-1 (ANGPT-1) and
urokinase (PLAU) genes in VEGF-ADSC. As shown in
Figure 6 we did not find any changes in FGF2 and HGF
expression in GFP-ADSC and VEGF-ADSC compared to
ADSC. We found a 3-fold increase in urokinase expres-
sion in VEGF-ADSC yet it was not statistically significant.
At the same time increase of ANGPT-1 expression in
VEGF-ADSC was significant and 5.3±0.6-fold higher than
in unmodified cells or GFP-ADSC (n=6, p<0.05).
Analysis of VEGF and PDGF receptors expression on ADSC
surface.
Analysis of VEGF receptors expression on human ADSC
was carried out to assess possible autocrine action of
VEGF on VEGF-ADSC functional properties. Flow cyto-
metry of ADSC and VEGF-ADSC (at passage 1–2) from
different donors stained for VEGF receptor 1 and 2
showed <1% of positive cells (Figure 7). Taking into
account observation of Ball et al. which indicated
platelet-derived growth factor receptors (PDGFRα and
PDGFRβ) as facultative receptors for VEGF165 [27] we
analyzed the presence of cells which expressed PDGFRβ
in human ADSC culture. Using specific monoclonal
antibodies and subsequent flow cytometry we found
that >90% of human ADSC were positive for PDGFRβ
(Figure 7).
Increased vascularisation of matrigel implants after VEGF-
ADSC transplantation.
We used matrigel plug assay to determine angiogenic
properties of gene modified ADSC in vivo. At day 14
Figure 3 Proliferation of gene modified ADSC. A. Population doubling time in GFP-ADSC, VEGF-ADSC and ADSC cultures. Data of five serial
runs. B. Cells distribution in S-G2 cell cycle stages according to cytometry analysis of GFP-ADSC, VEGF-ADSC and ADSC. Data of three serial runs.
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logical analysis (Figure 8). In negative control group we
found only small sporadic capillaries (<1 capillary per
FOV) were detected while in “ADSC”, “GFP-ADSC” and
“VEGF-ADSC” groups formation of vessel network wasFigure 4 Data from comparative study of ADSC, GFP-ADSC and VEGF
vitronectin, fibronectin or laminin (n=4).more evident. Vessel counts revealed a 2.7-fold increase of
CD31-positive vessels in group “VEGF-ADSC” (88.1±10.4
vessels per FOV) compared to “GFP-ADSC” (31.3±6.2
vessels per FOV) and “ADSC” (34.5±11.6 per FOV). Num-
ber of smooth muscle actin (SMA)-positive vessels was-ADSC adhesion on culture plates coated by collagen 1,
Figure 5 Adipogenic and osteogenic differentiation of gene modified ADSC. Representative images of ADSC and VEGF-ADSC cultures
stained by Oil Red O (lipid droplets detection, kjadipogenic differentiation, 100 ×magnification) and Alizarine Red C (matrix mineralization,
osteogenic differentiation, 100 × magnification for “day 14” and 50 ×magnification for “day 21”) reagents after incubation in specific differentiation
medium, n=3.
Figure 6 Comparison of ANGPT1, FGF2, PLAU and HGF genes expression by quantitative PCR in GFP-ADSC, VEGF-ADSC and
unmodified ADSC. Charts represent relative expression for assayed genes from a total of 6 runs.
Shevchenko et al. Journal of Translational Medicine 2013, 11:138 Page 9 of 18
http://www.translational-medicine.com/content/11/1/138
Figure 7 Analysis of VEGF and PDGF receptors expression on ADSC surface. VEGFR1, VEGFR2 or PDGFRβ-positive cell count by flow
cytometry in ADSC culture.
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per FOV) than in “GFP-ADSC” (0.7±0.3 vessels per FOV)
and “ADSC” (0.7±0.2 vessels per FOV). Thus capillaries/
SMA+vessels ratio did not vary among experimental
groups.
Blood flow recovery after VEGF-ADSC transplantation into
ischemic murine limb
Perfusion assessment in hind limb ischemia model
showed maximum blood flow recovery in “VEGF-ADSC”Figure 8 Effect of VEGF-ADSC or ADSC on vascularization of matrigel
sections from “VEGF-ADSC” and “ADSC” groups stained by antibodies again
arterioles count in matrigel implants.group (Figure 9). By day 20 spontaneous reperfusion of
ischemic limb in «PBS» group was feeble and did not
exceed 30%. In contrast we observed evident augmenta-
tion of blood supply in three experimental groups that
received cell injections. At the end of experiment per-
fusion in “ADSC” and “GFP-ADSC” groups reached 50%
and 55% respectively. Blood flow recovery after VEGF-
ADSC transplantation was much more effective. At day
12 perfusion in group “VEGF-ADSC” significantly ex-
ceeded values in “ADSC” and “GFP-ADSC” by 15-20%implants in nude mice. A. Representative images of matrigel
st murine CD31 and SMA, 100× magnification. B. Capillaries and
Figure 9 Reperfusion of murine ischemic limb after ADSC administration. A. Representative laser-doppler scans of subcutaneous blood flow
in mice from “ADSC” and “VEGF-ADSC” groups obtained at days 4 and 20 after ischemia induction and cell transplantation. B. Dynamics of blood
flow recovery in ischemic limbs within 20 days after intramuscular injection of ADSC, GFP-ADSC, VEGF-ADSC or PBS.
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80-90%. Thus transplantation of ADSC overexpressing
VEGF was more effective than of untreated or GFP-
ADSC.
Transplantation of VEGF-ADSC reduces necrosis and
stimulates stable vessel formation in ischemic muscle
Histological analysis of hematoxylin-eosin stained m.
tibialis anterior specimens obtained at day 20 after and
cell transplantation showed significant decrease in nec-
rotic tissue span in «VEGF-ADSC» group (31.3±7%) com-
pared to «ADSC» and «GFP-ADSC» groups (54.3±8.4%
and 55.63±6.8%). Animals that received PBS injection as a
negative control were characterized by the highest muscle
necrosis span that reached 84±6.7% (Figure 10).
To assess vascular density muscle tissue sections were
stained by specific antibodies against mouse CD31 and
SMA (Figure 11). Vessel count showed that in “ADSC”
and “GFP-ADSC” groups capillary and arteriolar densities
were similar reaching 129±11 and 125±14 capillaries/FOV,
1.35±0.12 and 1.37±0.09 arterioles/FOV respectively. In
specimens from animals that received VEGF-ADSC capil-
lary density was 189±19 per FOV (p<0.05) with arteriolar
density of 3.1±0.2 per FOV (p<0.01). Furthermore, we
found that arterioles/CD31+ vessels ratio was similar in all
experimental groups and slightly higher in group “VEGF-
ADSC” (1% vs 1.6%). In addition morphometric analysis
of muscle tissue from group “VEGF-ADSC” did not reveal
angioma or abnormal vessel formation.
ADSC retain viability and transgene expression after
transplantation into ischemic muscle
To evaluate viability of transplanted ADSC after injec-
tion into ischemic tissue m. tibialis anterior specimens
from “GFP-ADSC” group were harvested at day 7 after
induction of ischemia and cell transplantation. Frozenmuscle sections were analyzed using fluorescence
microscopy that allowed to detect GFP-positive cells
distributed throughout muscle (Figure 12A).
Data from experimental studies indicates that pro-
longed expression of therapeutic transgene is essential
for effective stimulation of angiogenesis and ischemic
tissue recovery. Muscle explant model was carried out to
confirm the presence of viable and functionally active
human ADSC overexpressing VEGF in ischemic muscle
at hind limb ischemia experiment endpoint. M. tibialis
anterior were harvested from “ADSC”, “GFP-ADSC” and
“VEGF-ADSC” group animals at day 3 and 20 after cell
transplantation and cultured as explant in matrigel. In
culture medium samples collected after 3 days of
“VEGF-ADSC” explant incubation (obtained at day 3
after cell transplantation) human VEGF165 concentra-
tion determined by ELISA reached 2.86±0.21 ng/ml
(Figure 12B). Protein concentration was expectedly lower
(0.145±0.015 ng/ml) in conditioned medium from muscle
explants harvested at day 20. In addition comparison of
VEGF concentration in culture medium samples collected
at day 3 and 7 post incubation of explant culture revealed
accumulation of VEGF. It indirectly confirms presence
of functionally active human VEGF-ADSC in ischemic
muscle up to 20 days post transplantation. In contrast to
“VEGF-ASDC” human VEGF165 concentration in explant
cultures from “GFP-ADSC” and “ADSC” groups was
below limit of detection.
Discussion
Gene modified cell-based therapy for ischemic disorders:
myocardium infarction and limb ischemia is a rapidly
evolving trend in experimental and regenerative medicine.
Promoting angiogenesis in ischemic tissues via paracrine
action of transplanted modified cells is an emerging alter-
native modality for patients who are unsuitable for
Figure 10 Morphometric analysis of tissue necrosis in ischemic muscle from study group animals. A. Images of hematoxylin-eosin
stained m. tibialis anterior sections. Necrotic tissue is marked by black line. (N* - necrotic tissue, B* - border zone, H* - healthy or regenerating tissue).
B. Representative images of muscle tissue from different zones of section. Labels: star – vasa in normal muscle tissue with; black dot – inflammatory
demarcation zone between anucleic disrupted tissue and regenerating muscle fibers; triangle – regenerating round-shaped muscle fibers with
multiple centrally located nuclei. C. Statistical data of necrotic tissue area in “PBS”, “ADSC”, “GFP-ADSC” and “VEGF-ADSC” groups. Measurements made
in 4–5 animals per group.
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Figure 11 Vascularization of murine ischemic muscles after ADSC administration. A. Representative images of m. tibialis anterior sections
from “VEGF-ADSC” and “ADSC” groups stained by antibodies against murine CD31 and SMA, 100× magnification. B. Capillaries and arterioles
count in m. tibialis anterior sections. Counts made in 5–6 animals per group.
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of appropriate cell type, angiogenic factor and gene deli-
very tool are crucial issues for efficacy and safety of the
method.
Regarding type of cells there are certain issues
concerning their derivation and preparation prior to
grafting. Thus, embryonic stem cells application is
doubtful due to ethical reasons, potential risks of tera-
togenesis and immune response to their differentiated
progenies [28]. Use of endothelial progenitor cells from
peripheral blood and bone marrow are limited by expen-
sive procedures of isolation and difficulties in obtaining
sufficient amount of cells. Regarding the latter point it is
known that prolonged incubation of cells in vitro prior
to transplantation is associated with potential risks of
malignancy, proliferation decrease and commitment to
terminal differentiation. Use of skeletal myoblasts or bone
marrow derived mesenchymal stromal cells (BMMSC) is
associated with painful isolation procedure of muscle
biopsy and suprailiac puncture respectively.
ADSC used in our study share a lot of similar proper-
ties and characteristics with BMMSC, while they are
easier to obtain in sufficient quantity using minimally
invasive liposuction procedure. Various data suggests
that up to 1.5 × 106 adipose stromal cells can be isolated
from 1 ml of adipose tissue [29,30]. This allows to
reduce the time of cell propagation in vitro prior to
transplantation. As for therapeutic angiogenesis, humanADSC produce a wide spectrum of biologically active
molecules – angiogenic growth factors, cytokines, prote-
ases etc. [31,32]. Multiple experimental studies accu-
mulate data on relatively high therapeutic potential of
ADSC for tissue regeneration and stimulation of angio-
genesis [21,33,34]. However well-known reduction of cell
regenerative potential with age and among patients with
severe co-morbidities is also relevant for ADSC. Donor
age-associated decrease of proliferation activity and
differentiation capabilities was shown for human ADSC
[35,36]. Angiogenic potential of ADSC also decreases
with ageing and is characterized by reduced secretion of
VEGF, HGF, angiopoietin-1 and other angiogenic factors
[37]. Thus, attempts to improve regenerative potential of
ADSC are reasonable.
We have shown high efficacy of rAAV-mediated
genetic modification of human ADSC. Using rAAV
encoding VEGF165 we obtained human ADSC with
increased level of VEGF165 secretion which retained for
at least 30 days. VEGF-A and particularly its most abun-
dant 165-amino acid isoform triggers multiple reactions
promoting new vessel formation and growth [23] that
supported our choice of therapeutic gene in presented
study. Observed gradual decrease of transgene expres-
sion can be attributed to proliferation activity of ADSC
together with known episomal subsistence of rAAV [38].
Moreover cellular mechanism of addressed methylation
can be activated after transduction leading to suppression
Figure 12 Human ADSC viability and VEGF expression after transplantation to ischemic murine muscle. A. Representative image of
m. tibialis anterior section from “GFP-ADSC” group obtained at day 7 after ischemia induction and GFP-ADSC injection, 50× magnification.
GFP-positive cells are distributed in tissue around injection site. B. Analysis of VEGF165 content by ELISA in explants culture medium from “ADSC”,
“GFP-ADSC”, “VEGF-ADSC” groups obtained at days 3 and 20 after cell trasplantation.
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expression in our vector [39].
Potential influence of genetic modification and trans-
gene expression on cell behavior and functional activity
is frequently kept out of consideration while this issue is
of great importance, especially for potential clinical
application. We examined possible effects of rAAV-
transduction and VEGF overexpression on functional
properties of ADSC which included proliferation,
spontaneous apoptosis, adhesion and differentiation
capability.
We observed a decline in ADSC proliferation after
modification by rAAV that was evident by increase of
population doubling time as well as decrease in number
of cells in S–G2 stages of cell cycle. At the same time
spontaneous apoptosis rate did not exceed 2% in modifiedand unmodified cells. These results contribute to pre-
viously published data that showed transient cell cycle
arrest after AAV transduction of embryonic fibroblasts
and BMMSC [40]. This effect was observed whenever
wild-type, recombinant or genome-empty AAV particles
were used. It was suggested that changes in expression
profile and decreased proliferation were related to initial
stage of virus entry and caused by capsid proteins inter-
action with cellular signaling pathways [40]. Growth
inhibitory effect was transient and proliferation restored
to normal level over time of cell passaging [41]. It appears
that proliferation decline of rAAV-modified ADSC occurs
by a common mechanism.
ADSC are known to be able to differentiate into adipo-
cytes, chondrocytes, osteoblasts, myocytes, neural cells,
cardiomyocytes, endothelial and liver cells when cultured
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our differentiation experiments we concluded that rAAV-
mediated genetic modification of human ADSC and
VEGF overexpression did not alter their adipogenic and
osteogenic differentiation properties.
There are several observations indicating ability of
ADSC for endothelial differentiation [44,45] as well as
evidence for presence of small amount of endothelial
cells in ADSC population at early passages [18,19]. In
our experiments we did not find an increase in amount
of cells positive for endothelial markers CD31 and
VEGFR2 in VEGF-ADSC compared to unmodified
ADSC population. This suggests that VEGF overex-
pression neither induces endothelial differentiation of
modified ADSC nor stimulates proliferation of pre-
existing endothelial cells in ADSC culture.
Adhesion tests conducted in our study were based on
a fact that interaction with extracellular matrix proteins
is a key factor that contributes to cell viability and
integration into host tissue after transplantation [46].
We found that both modified and untreated ADSC
showed very common adhesion on collagen type 1,
vitronectin and fibronectin. Thus we can suggest that
rAAV-mediated genetic modification did not alter ex-
pression of adhesion molecules on cell surface of ADSC.
Our results showing low ADSC adhesion on laminin are
not surprising taking into account published observa-
tions which indicate diminished or lack of α6, α7 and ß1
integrins expression in ADSC-components of α6/ß1 and
α7/ß1 receptors for laminin [47,48].
Since VEGF can regulate multiple signaling pathways
[23] we next determined whether expression of HGF,
FGF2, urokinase and angiopoietin-1 might be altered in
VEGF-ADSC. HGF and FGF2 are mitogens and che-
moattractants for both endothelial and mural cells and
directly participate in angio- and arteriogenesis [4].
Angiopoietin-1 is characterized as a stabilizing factor
that provides formation of functionally mature vessel
network [49]. Urokinase plasminogen activator is a key
regulator of extracellular proteolysis which is responsible
for cleavage activation of growth factors and migration
of endothelial cells during vessel growth [50,51]. We
found almost 3-fold yet not statistically significant
increase of urokinase expression while expression of
HGF and FGF2 did not change. Another interesting
finding is a 5-fold increase of angiopoietin-1 expression
in VEGF–ADSC compared to GFP–ADSC or unmodi-
fied cells.
We assumed that up-regulation of angiopoietin-1
expression occurs due to autocrine action of VEGF165
produced by VEGF-ADSC. However according to our
data supported by other studies [30,52] cultured human
ADSC population contains <1% of cells that express
receptors to VEGF165 - VEGFR1 and VEGFR2. At thesame time we found that >90% of ADSC carry receptor
to platelet-derived growth factor - PDGFRβ. There is a
published observation that PDGFRα and PDGFRβ can
act as a facultative receptor for VEGF [27]. Furthermore
it is known that PDGFR activation leads to increase of
angiopoietin-1 expression [53]. Considering that more
than 90% of human ADSC are PDGFRβ-positive we can
speculate that increased expression of angiopoetin-1 in
VEGF-ADSC could be attributed to PDGFRβ-mediated
autocrine action of VEGF.
In our study we evaluated therapeutic potential of
gene modified human ADSC in terms of their ability to
induce angiogenesis in ischemic muscle tissue. It was
found that matrigel implants after transplantation of
VEGF-ADSC had higher vascular density than after
delivery of untreated cells or ADSC transduced by a
reporter gene. Along with capillary formation we also
found proportional increase in amount of mature blood
vessels characterized by smooth-muscle wall. This can
occur due to the fact that cells transplanted in matrigel
produce other angiogenic factors besides VEGF that can
promote vessel maturation and stabilization.
Key angiogenic property of cell therapies in experi-
mental study is ability to induce reperfusion of ischemic
tissue in appropriate animal models. We used hind limb
ischemia model to show that VEGF-ADSC transplan-
tation led to significantly higher perfusion restoration
than after untreated of GFP-transduced cell administra-
tion. It was also found that intramuscular injection of
VEGF-ADSC had a tissue-protective effect and led to
vivid decrement of necrosis span. VEGF is known to be
significant antiapoptotic factor that can enhance cell
survival. We suggest that increased VEGF content
during the first days after onset of acute ischemia and
cells administration leads to promotion of cell survival
and thus to reduction of necrotic disruption in muscle
tissue.
We should also point that during the experiment we
did not observe any blood flow decrease after cell
administration or rapid “plateau” formation like it was
previously described for plasmid-mediated gene delivery
due to short-term transgene expression [4]. This can be
explained by presence of viable and functionally active
ADSC that produced VEGF throughout the experiment.
In our muscle explant experiments we showed that
VEGF-ADSC retain functional activity even at long
terms after injection (up to 27 days) and produce VEGF
in detectable quantities. Thus we can confidently attri-
bute tissue protection and restoration of blood flow in
mice that received VEGF-ADSC to increased long-term
VEGF production by modified cells. As for decrease of
human VEGF content in murine tissue by day 20 we
suggest that cells undergo apoptosis over time. Besides
that methylation of CMV promoter which drives VEGF
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account that Nude mice were used we find it hard to
assume possible rejection of transplanted cells as far as
this animal strain lacks T-cells immunity which plays a
crucial role in graft rejection. Still, it seems that produced
amount of VEGF is sufficient to trigger angiogenesis and
relief tissue ischemia via restoration of blood flow.
Histological analysis of ischemic muscle injected with
modified VEGF-ADSC revealed that capillary density
was significantly higher than in specimens from animals
that received untreated cells or GFP-ADSC. We noticed
that this increase was not only due to higher capillary
count, but also to SMA-positive blood vessels of
arteriolar type. Furthermore arteriole/capillary ratio was
constant throughout experimental groups that indicated
formation of a stable mature vascular network. Thus,
despite high level of VEGF produced by modified ADSC
we did not observe any evidence for abnormal tumour-
like vascular structures in muscle as it was previously
shown e.g. in studies of adenovirus-mediated delivery of
VEGF gene [54]. In contrast to matrigel implants expe-
riment in case of skeletal muscle we do not state that
increase of vascular density in experimental groups was
only due to de novo formed vessels. Besides promoting
endothelial cell proliferation VEGF also prevents en-
dothelial apoptosis leading to survival of preexisting
vessels. There was surely a vast amount of persisted
capillaries in the muscles due to VEGF anti-apoptotic
effect of VEGF.
It is often speculated that low efficacy reported in
clinical trials using gene delivery of VEGF alone can be
explained by its high mitogenic activity which is not
supported by vessel stabilizing stimuli and consequently
ends up with dissociation of formed capillaries [55]. This
led to a concept of combined gene delivery indicating
that combinations of angiogenic and vascular stabilizing
factors should be used to treat ischemic tissues [55-58].
Cell therapy for ischemic disorders has a valuable advan-
tage since transplanted cells produce a whole “cocktail”
of biologically active molecules which render combined
effect in impaired tissue. We suggest that stable vessel
formation observed in our study is mediated by afore-
mentioned ADSC ability to produce a wide spectrum of
angiogenic factors including ones responsible for vessel
stabilization and maturation: angiopoietin-1, TGF-β,
PDGF, which can act synergistically with increased
production of VEGF165 by modified cells. Besides that,
genetic modification can alter cell’s expression profile.
Observed increase in expression of angiopoietin-1 in
VEGF-ADSC can further contribute to formation of
mature vascular network that also supports therapeutic
effect of transplanted cells. Increased concentration of
VEGF in ischemic tissue plays a substantial role in vessel
stabilization and therapeutic effect if maintained over asignificant period of time, which was achieved in our
study and exceeded a substantial term of 3 weeks.
Conclusions
Thus we can conclude that human ADSC with their
accessibility and angiogenic paracrine activity is an
appropriate and preferable type of cells for therapeutic
angiogenesis. Obtained results indicate that relatively
safe rAAV holds great potential for gene transfer into
human ADSC. Taken together, we suggest that the use
of AAV-modified ADSC overexpressing VEGF165 is a
feasible and effective approach for stimulation of stable
vascular network formation in ischemic muscle and
can be implied for therapeutic angiogenesis or tissue-
engineered transplants. Further study and improvements
in vector design, regulated transgene expression, cell
preparation and propagation conditions are still to be
completed to allow clinical application of modified cell-
based therapeuticals.
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